[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 53
1. Von Behren J, Spector LG, Mueller BA, Carozza SE, Chow EJ, Fox EE, Horel S, Johnson KJ, McLaughlin C, Puumala SE, Ross JA, Reynolds P: Birth order and risk of childhood cancer: a pooled analysis from five US States. Int J Cancer; 2011 Jun 1;128(11):2709-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For children in the fourth or higher birth order category compared to first-born children, the adjusted OR was 0.87 (95% CI: 0.81, 0.93) for all cancers combined.
  • We observed increased risks with increasing birth order for acute myeloid leukemia but a slight decrease in risk for acute lymphoid leukemia.

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 UICC.
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1928-34 [16103439.001]
  • [Cites] Cancer Causes Control. 2005 Nov;16(9):1075-83 [16184473.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1281-6 [16835324.001]
  • [Cites] Cancer Causes Control. 2006 Dec;17(10):1267-74 [17111258.001]
  • [Cites] Neurology. 2006 Dec 12;67(11):1979-83 [17159104.001]
  • [Cites] Am J Epidemiol. 2007 Mar 1;165(5):496-504 [17182983.001]
  • [Cites] Eur J Pediatr. 2001 Jun;160(6):333-8 [11421411.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1428-37 [11821358.001]
  • [Cites] Cancer Causes Control. 2002 Feb;13(1):15-25 [11899114.001]
  • [Cites] Am J Epidemiol. 2002 Apr 1;155(7):603-13 [11914187.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1064-9 [11953850.001]
  • [Cites] J Pediatr. 2003 Jan;142(1):31-5 [12520251.001]
  • [Cites] JAMA. 2004 Mar 3;291(9):1127-31 [14996783.001]
  • [Cites] Epidemiology. 2004 May;15(3):323-9 [15097013.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 20;96(20):1549-56 [15494605.001]
  • [Cites] Child Dev. 1979 Sep;50(3):632-42 [498842.001]
  • [Cites] J Natl Cancer Inst. 1986 Jun;76(6):1035-9 [3458941.001]
  • [Cites] Leukemia. 1988 Feb;2(2):120-5 [3278171.001]
  • [Cites] Cancer. 1988 Aug 1;62(3):635-44 [3164642.001]
  • [Cites] Radiat Prot Dosimetry. 2008;132(2):267-72 [18945723.001]
  • [Cites] Paediatr Perinat Epidemiol. 2009 Mar;23(2):125-43 [19159399.001]
  • [Cites] Cancer Causes Control. 2009 Mar;20(2):129-36 [18766446.001]
  • [Cites] Epidemiology. 2009 Jul;20(4):475-83 [19373093.001]
  • [Cites] Int J Cancer. 2010 Jun 1;126(11):2752-6 [19830691.001]
  • [Cites] Br J Cancer. 2010 Jun 29;103(1):136-42 [20531410.001]
  • [Cites] J Pediatr. 2010 Sep;157(3):450-5 [20553692.001]
  • [Cites] BMJ. 2005 Jun 4;330(7503):1294 [15849205.001]
  • [Cites] Cancer Res. 1990 May 1;50(9):2608-12 [2328486.001]
  • [Cites] Cancer Causes Control. 1990 Sep;1(2):119-24 [2102281.001]
  • [Cites] J Clin Epidemiol. 1991;44(11):1159-66 [1941011.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Jul-Aug;4(5):441-5 [7549797.001]
  • [Cites] Cancer Causes Control. 1996 Jul;7(4):437-48 [8813432.001]
  • [Cites] Ann Epidemiol. 1997 Apr;7(3):172-9 [9141639.001]
  • [Cites] J Natl Cancer Inst. 1997 Jul 2;89(13):939-47 [9214673.001]
  • [Cites] Semin Cancer Biol. 1998 Aug;8(4):237-44 [9870030.001]
  • [Cites] J Clin Invest. 1999 Jul;104(1):41-7 [10393697.001]
  • [Cites] Paediatr Perinat Epidemiol. 1999 Jul;13(3):325-41 [10440052.001]
  • [Cites] Eur J Cancer. 2005 Mar;41(5):749-59 [15763652.001]
  • [Cites] Leuk Lymphoma. 2007 Dec;48(12):2387-96 [18067015.001]
  • [Cites] Leuk Lymphoma. 2007 Dec;48(12):2306-7 [18067003.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1457-67 [15712273.001]
  • [Cites] Int J Cancer. 2008 May 15;122(10):2315-21 [18076072.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2600-6 [18324625.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R8 [18205956.001]
  • [Cites] Cancer Detect Prev. 2008;32(1):79-86 [18396378.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):179-81 [18560404.001]
  • [Cites] Br J Cancer. 2008 Sep 2;99(5):796-9 [18728669.001]
  • (PMID = 20715170.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01CA717450; United States / NCI NIH HHS / CA / T32 CA099936-08; United States / NCI NIH HHS / CA / R01 CA071745; United States / NCI NIH HHS / CA / CA099936-08; United States / NCI NIH HHS / CA / R01 CA071745-04; United States / NCCDPHP CDC HHS / DP / U58 DP000783; United States / NCI NIH HHS / CA / R01 CA092670-01; United States / NCI NIH HHS / CA / CA092670-01; United States / NCCDPHP CDC HHS / DP / U58DP000783-01; United States / NCI NIH HHS / CA / R01CA92670; United States / NCI NIH HHS / CN / N01-CN-05230; United States / NCI NIH HHS / CA / R01 CA092670; United States / NCI NIH HHS / CA / T32 CA099936; United States / NCI NIH HHS / CA / CA071745-04; United States / NCI NIH HHS / CN / N01 CN005230
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS230557; NLM/ PMC3008504
  •  go-up   go-down


2. Slater ME, Linabery AM, Spector LG, Johnson KJ, Hilden JM, Heerema NA, Robison LL, Ross JA: Maternal exposure to household chemicals and risk of infant leukemia: a report from the Children's Oncology Group. Cancer Causes Control; 2011 Aug;22(8):1197-204
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maternal exposure to household chemicals and risk of infant leukemia: a report from the Children's Oncology Group.
  • OBJECTIVE: Utilizing data from the largest study to date, we examined associations between maternal preconception/prenatal exposure to household chemicals and infant acute leukemia.
  • METHODS: We present data from a Children's Oncology Group case-control study of 443 infants (<1 year of age) diagnosed with acute leukemia [including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)] between 1996 and 2006 and 324 population controls.
  • RESULTS: We did not find evidence for an association between infant leukemia and eight of nine chemical categories.
  • However, exposure to petroleum products during pregnancy was associated with AML (OR = 2.54; 95% CI:1.40-4.62) and leukemia without mixed lineage leukemia (MLL) gene rearrangements ("MLL-") (OR = 2.69; 95% CI: 1.47-4.93).
  • CONCLUSIONS: Gestational exposure to petroleum products was associated with infant leukemia, particularly AML, and MLL- cases.
  • Benzene is implicated as a potential carcinogen within this exposure category, but a clear biological mechanism has yet to be elucidated.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Household Products.
  • MedlinePlus Health Information. consumer health - Reproductive Hazards.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroepidemiology. 1999;18(6):292-302 [10545781.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4411-3 [10781030.001]
  • [Cites] Biofactors. 2000;12(1-4):193-9 [11216486.001]
  • [Cites] FEBS Lett. 2001 Mar 2;491(3):252-6 [11240137.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2542-6 [11289128.001]
  • [Cites] Epidemiology. 2002 May;13(3):277-81 [11964928.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1786-94 [12365028.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2321-33 [12791663.001]
  • [Cites] Am J Epidemiol. 1984 Jul;120(1):164-6 [6741917.001]
  • [Cites] Cancer. 1989 May 15;63(10):1904-11 [2649219.001]
  • [Cites] J Stud Alcohol. 1990 Sep;51(5):403-7 [2232792.001]
  • [Cites] Int J Epidemiol. 1994 Dec;23(6):1218-25 [7721524.001]
  • [Cites] J Natl Cancer Inst. 1996 Jan 3;88(1):24-31 [8847721.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):201-7 [8630931.001]
  • [Cites] Br J Cancer. 1997;76(9):1241-7 [9365177.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4 [9391133.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):651-5 [15767345.001]
  • [Cites] Paediatr Perinat Epidemiol. 2006 Mar;20(2):110-8 [16466429.001]
  • [Cites] J Pediatr. 2006 May;148(5):618-22 [16737872.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1902-5 [17855712.001]
  • [Cites] Nat Rev Cancer. 2007 Nov;7(11):823-33 [17957188.001]
  • [Cites] Environ Health Perspect. 2007 Dec;115(12):1767-79 [18087597.001]
  • [Cites] Cancer. 2008 Jan 15;112(2):416-32 [18074355.001]
  • [Cites] Blood Cells Mol Dis. 2008 Mar-Apr;40(2):192-9 [17905612.001]
  • [Cites] J Anal Toxicol. 2008 Sep;32(7):511-5 [18713520.001]
  • [Cites] Am J Epidemiol. 2009 Aug 1;170(3):379-87 [19498073.001]
  • [Cites] Annu Rev Public Health. 2010;31:133-48 2 p following 148 [20070208.001]
  • [Cites] Chem Biol Interact. 2010 Mar 19;184(1-2):151-64 [20067778.001]
  • [Cites] Blood. 2010 Apr 8;115(14):2835-44 [20032505.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1238-60 [20447918.001]
  • [Cites] Hum Reprod. 2010 Jun;25(6):1561-8 [20382971.001]
  • [Cites] Pediatr Blood Cancer. 2010 Jul 15;55(1):95-9 [20486175.001]
  • [Cites] Cancer Treat Rev. 2010 Jun;36(4):286-97 [20223594.001]
  • (PMID = 21691732.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA013539; United States / NCI NIH HHS / CA / P30 CA77598; United States / NCI NIH HHS / CA / U10 CA98413; United States / NCI NIH HHS / CA / P30 CA077598; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA13539; United States / NCI NIH HHS / CA / R01 CA079940; United States / NCI NIH HHS / CA / T32 CA99936; United States / NCI NIH HHS / CA / T32 CA099936; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / R01 CA79940; United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS775386; NLM/ PMC4836386
  •  go-up   go-down


3. Pui CH, Pei D, Pappo AS, Howard SC, Cheng C, Sandlund JT, Furman WL, Ribeiro RC, Spunt SL, Rubnitz JE, Jeha S, Hudson MM, Kun LE, Merchant TE, Kocak M, Broniscer A, Metzger ML, Downing JR, Leung W, Evans WE, Gajjar A: Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007. J Clin Oncol; 2012 Jun 1;30(16):2005-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: In a parallel comparison, we analyzed survival by disease category between black and white patients with childhood cancer registered in one of the 17 cancer registries of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program or treated at St Jude Children's Research Hospital, which provides comprehensive treatment to all patients regardless of their ability to pay, from 1992 to 2000 and from 2001 to 2007.
  • Despite significantly improved treatment outcomes for patients who were treated from 2001 to 2007, the racial difference in survival has actually widened for acute myeloid leukemia and neuroblastoma.
  • Importantly, the outcome of treatment for acute lymphoblastic leukemia, acute myeloid leukemia, and retinoblastoma has improved in parallel for both races during the most recent study period.

  • MedlinePlus Health Information. consumer health - African American Health.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuro Oncol. 2011 Apr;13(4):410-6 [21345842.001]
  • [Cites] Nat Genet. 2011 Mar;43(3):237-41 [21297632.001]
  • [Cites] CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36 [21685461.001]
  • [Cites] Blood. 2011 Jul 14;118(2):223-30 [21613256.001]
  • [Cites] Nat Rev Clin Oncol. 2011 Sep;8(9):540-9 [21709698.001]
  • [Cites] Cancer. 2012 Feb 1;118(3):761-9 [21766293.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1339-45 [12599243.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):603-9 [12879479.001]
  • [Cites] JAMA. 2003 Oct 15;290(15):2001-7 [14559953.001]
  • [Cites] JAMA. 2003 Oct 15;290(15):2008-14 [14559954.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4200-6 [14615448.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):621-30 [14745881.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4036-42 [14976037.001]
  • [Cites] Pediatrics. 2004 Jun;113(6):1833-5 [15173520.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] JAMA. 1995 Feb 22;273(8):633-7 [7844873.001]
  • [Cites] J Pediatr. 1997 Oct;131(4):603-7 [9386667.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4021-30 [15767645.001]
  • [Cites] Blood. 2006 Jul 1;108(1):74-80 [16537811.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jan;48(1):10-5 [16642489.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3589-95 [17704406.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1044-53 [18000167.001]
  • [Cites] J Clin Oncol. 2008 Mar 10;26(8):1282-8 [18323551.001]
  • [Cites] Pediatr Dev Pathol. 2008 Mar-Apr;11(2):108-17 [17990938.001]
  • [Cites] Semin Oncol. 2008 Oct;35(5):484-93 [18929147.001]
  • [Cites] Cancer. 2008 Nov 1;113(9):2575-96 [18837040.001]
  • [Cites] N Engl J Med. 2009 Jun 25;360(26):2730-41 [19553647.001]
  • [Cites] J Clin Oncol. 2010 May 20;28(15):2625-34 [20404250.001]
  • [Cites] Lancet Oncol. 2010 Jun;11(6):543-52 [20451454.001]
  • [Cites] N Engl J Med. 2010 Sep 30;363(14):1324-34 [20879881.001]
  • [Cites] Blood. 2010 Dec 16;116(25):5501-6 [20823456.001]
  • [Cites] J Clin Oncol. 2011 Jan 1;29(1):76-82 [21098321.001]
  • [Cites] Pediatr Blood Cancer. 2011 Mar;56(3):425-31 [21072824.001]
  • [Cites] Neuro Oncol. 2011 Mar;13(3):317-23 [21339192.001]
  • [Cites] Prostate. 2011 Jun 15;71(9):985-97 [21541975.001]
  • (PMID = 22547602.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R37 CA036401; United States / NCI NIH HHS / CA / CA36401; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / P30 CA021765; United States / NIGMS NIH HHS / GM / U01GM92666; United States / NCI NIH HHS / CA / R01 CA036401; United States / NIGMS NIH HHS / GM / U01 GM092666
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3383176
  •  go-up   go-down


Advertisement
4. Anwar N, Arshad A, Nadeem M, Khurram S, Fatima N, Sharif S, Shan S, Shamsi T: Clinicohematological and cytogenetic profile of myelodysplastic syndromes in Pakistan-compare and contrast. Mol Cytogenet; 2017;10:17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A retrospective cross sectional study was done at National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, Pakistan from 2010 to 2016.
  • Refractory cytopenias with multilineage dysplasia (RCMD) was the most common world health organization (WHO) category.
  • CK and monosomy 7 carry bad prognostic implications and early disease transformation to acute myeloid leukemia (AML).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2005 May;19(5):767-75 [15759035.001]
  • [Cites] Leuk Lymphoma. 2007 Jul;48(7):1372-8 [17613766.001]
  • [Cites] Indian J Med Res. 2011 Oct;134:452-7 [22089606.001]
  • [Cites] Asian Pac J Cancer Prev. 2016;17 (3):1049-52 [27039723.001]
  • [Cites] J Coll Physicians Surg Pak. 2010 Apr;20(4):232-6 [20392397.001]
  • [Cites] Blood. 2013 Oct 24;122(17):2943-64 [23980065.001]
  • [Cites] Leukemia. 2008 Mar;22(3):544-50 [18094713.001]
  • [Cites] Leukemia. 2003 Feb;17(2):305-13 [12592327.001]
  • [Cites] Br J Haematol. 2000 Feb;108(2):346-56 [10691865.001]
  • [Cites] Ann Hematol. 2013 Jul;92(7):877-87 [23572136.001]
  • [Cites] J Coll Physicians Surg Pak. 2014 Sep;24(9):632-5 [25233965.001]
  • [Cites] Acta Haematol. 2015;134(2):125-34 [25925777.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4638-41 [12036901.001]
  • [Cites] Ann Acad Med Singapore. 2004 Sep;33(5):589-95 [15531954.001]
  • [Cites] Leuk Res. 2011 Dec;35(12):1591-6 [21708407.001]
  • [Cites] Asian Pac J Cancer Prev. 2016;17 (3):1535-7 [27039802.001]
  • (PMID = 28491138.001).
  • [ISSN] 1755-8166
  • [Journal-full-title] Molecular cytogenetics
  • [ISO-abbreviation] Mol Cytogenet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Clinicohematological characteristics / Cytogenetics / Karyotype / Myelodysplastic syndromes
  •  go-up   go-down


5. Lin TL, Levy MY: Acute myeloid leukemia: focus on novel therapeutic strategies. Clin Med Insights Oncol; 2012;6:205-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia: focus on novel therapeutic strategies.
  • Acute myeloid leukemia (AML) is a heterogeneous disease with variable clinical outcomes.
  • Cytogenetic analysis reveals which patients may have favorable risk disease, but 5-year survival in this category is only approximately 60%, with intermediate and poor risk groups faring far worse.
  • Advances in our understanding of the biology of leukemia pathogenesis and prognosis have not been matched with clinical improvements.
  • Potential leukemia stem cell targeted therapies and treatments in the setting of minimal residual disease are also under investigation.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1969-78 [15632409.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1416-24 [15746041.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8403-12 [16322302.001]
  • [Cites] Blood. 2006 Jul 1;108(1):63-73 [16522815.001]
  • [Cites] Leuk Res. 2007 Feb;31(2):257-9 [16620971.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3904-11 [16921041.001]
  • [Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4048-53 [17360475.001]
  • [Cites] Curr Treat Options Oncol. 2007 Aug;8(4):296-304 [18058075.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1638-45 [18565853.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4934-9 [18591543.001]
  • [Cites] Eur J Haematol. 2012 Jan;88(1):52-60 [21883483.001]
  • [Cites] J Clin Oncol. 2011 Nov 20;29(33):4417-23 [21969499.001]
  • [Cites] Cancer Chemother Rep. 1973 Nov-Dec;57(4):485-8 [4586956.001]
  • [Cites] Blood. 1981 Dec;58(6):1203-12 [6946847.001]
  • [Cites] Bone Marrow Transplant. 2009 Jul;44(1):13-7 [19139740.001]
  • [Cites] Nature. 2009 Apr 9;458(7239):776-9 [19169242.001]
  • [Cites] Blood. 2009 Jul 30;114(5):937-51 [19357394.001]
  • [Cites] Am J Hematol. 2009 Sep;84(9):599-600 [19650144.001]
  • [Cites] Cancer. 2009 Dec 15;115(24):5746-51 [19795507.001]
  • [Cites] PLoS One. 2010;5(12):e15262 [21203400.001]
  • [Cites] J Clin Oncol. 2011 Feb 10;29(5):495-503 [21220600.001]
  • [Cites] Blood. 2011 Mar 24;117(12):3294-301 [21270442.001]
  • [Cites] Biol Blood Marrow Transplant. 2011 Sep;17(9):1404-9 [21324374.001]
  • [Cites] Blood. 2011 Jul 21;118(3):523-8 [21551228.001]
  • [Cites] Oncologist. 2011;16(8):1162-74 [21765192.001]
  • [Cites] Leuk Res. 2010 Jul;34(7):877-82 [19962759.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):521-3 [20026796.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):556-61 [20026803.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):562-9 [20026804.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):549-55 [20026805.001]
  • [Cites] Leuk Res. 2010 Sep;34(9):1214-23 [20138667.001]
  • [Cites] Leukemia. 2010 May;24(5):1025-36 [20200556.001]
  • [Cites] J Clin Oncol. 2010 May 10;28(14):2389-95 [20385984.001]
  • [Cites] Blood. 2010 Dec 9;116(24):5089-102 [20705759.001]
  • [Cites] Biol Blood Marrow Transplant. 2011 Jun;17(6):893-900 [20946966.001]
  • [Cites] J Clin Oncol. 2010 Nov 20;28(33):4919-25 [20956622.001]
  • [Cites] J Clin Oncol. 2011 Feb 1;29(4):369-77 [21172891.001]
  • [Cites] Blood. 1992 Apr 15;79(8):1924-30 [1562720.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Nature. 2001 May 17;411(6835):349-54 [11357142.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):324-31 [15549094.001]
  • [Cites] N Engl J Med. 2005 Jan 20;352(3):254-66 [15659725.001]
  • [Cites] Blood. 2006 Jul 1;108(1):45-51 [16403905.001]
  • [Cites] Blood. 2006 May 1;107(9):3481-5 [16455952.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2264-5; author reply 2265 [17312001.001]
  • [Cites] Nat Med. 2007 Aug;13(8):944-51 [17632527.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1909-18 [18450602.001]
  • [Cites] Clin Cancer Res. 2008 May 15;14(10):3077-82 [18483374.001]
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1235-48 [19776405.001]
  • [Cites] N Engl J Med. 2009 Sep 24;361(13):1249-59 [19776406.001]
  • [Cites] Blood. 2010 Jan 21;115(3):453-74 [19880497.001]
  • [Cites] J Clin Oncol. 2010 Feb 10;28(5):808-14 [20048183.001]
  • [Cites] Blood. 2011 Jun 30;117(26):7007-13 [21518931.001]
  • [Cites] Blood. 2011 Aug 11;118(6):1472-80 [21613261.001]
  • [Cites] CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36 [21685461.001]
  • [Cites] Blood. 2011 Oct 13;118(15):4258-64 [21841163.001]
  • [Cites] Leukemia. 2012 Mar;26(3):381-9 [21886171.001]
  • [Cites] Br J Haematol. 2012 Jan;156(2):205-12 [22082314.001]
  • [Cites] Blood. 2012 Apr 26;119(17):3917-24 [22308295.001]
  • [Cites] Cancer Cell. 2011 Nov 15;20(5):674-88 [22094260.001]
  • [Cites] N Engl J Med. 1994 Oct 6;331(14):896-903 [8078551.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1302-11 [11520775.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1752-9 [11535508.001]
  • [Cites] Arch Intern Med. 2002 Jul 22;162(14):1597-603 [12123403.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4372-80 [12393388.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):775-7 [12780793.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2379-86 [12791647.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4496-504 [14673036.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):624-33 [14726504.001]
  • [Cites] Blood. 2005 Feb 1;105(3):940-7 [15486072.001]
  • (PMID = 22654526.001).
  • [ISSN] 1179-5549
  • [Journal-full-title] Clinical Medicine Insights. Oncology
  • [ISO-abbreviation] Clin Med Insights Oncol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3362331
  • [Keywords] NOTNLM ; FLT3 / acute myeloid leukemia / cancer stem cells / clofarabine / gemtuzumab ozogamicin
  •  go-up   go-down


6. Khalade A, Jaakkola MS, Pukkala E, Jaakkola JJ: Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis. Environ Health; 2010;9:31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis.
  • BACKGROUND: A substantial number of epidemiologic studies have provided estimates of the relation between exposure to benzene at work and the risk of leukemia, but the results have been heterogeneous.
  • To bridge this gap in knowledge, we synthesized the existing epidemiologic evidence on the relation between occupational exposure to benzene and the risk of leukemia, including all types combined and the four main subgroups acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML).
  • The summary effect size for any leukemia from the fixed-effects model was 1.40 (95% CI, 1.23-1.57), but the study-specific estimates were strongly heterogeneous (I2 = 56.5%, Q stat = 34.47, p = 0.003).
  • In these studies the risk of leukemia increased with a dose-response pattern with a summary-effect estimate of 1.64 (95% CI, 1.13-2.39) for low (< 40 ppm-years), 1.90 (95% CI, 1.26-2.89) for medium (40-99.9 ppm-years), and 2.62 (95% CI, 1.57-4.39) for high exposure category (> 100 ppm-years).
  • The risk of AML also increased from low (1.94, 95% CI, 0.95-3.95), medium (2.32, 95% CI, 0.91-5.94) to high exposure category (3.20, 95% CI, 1.09-9.45), but the trend was not statistically significant.
  • CONCLUSIONS: Our study provides consistent evidence that exposure to benzene at work increases the risk of leukemia with a dose-response pattern.
  • [MeSH-major] Benzene / toxicity. Leukemia / chemically induced. Occupational Exposure / adverse effects
  • [MeSH-minor] Humans. Leukemia, Lymphocytic, Chronic, B-Cell / chemically induced. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / chemically induced. Leukemia, Myeloid, Acute / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / chemically induced. Risk Factors

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. BENZENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Occup Environ Med. 1996 Nov;53(11):773-81 [9038803.001]
  • [Cites] Environ Health Perspect. 1989 Jul;82:289-97 [2676500.001]
  • [Cites] Epidemiology. 1997 May;8(3):318-20 [9115030.001]
  • [Cites] Occup Environ Med. 1997 Mar;54(3):152-66 [9155776.001]
  • [Cites] J Natl Cancer Inst. 1997 Jul 16;89(14):1065-71 [9230889.001]
  • [Cites] Occup Environ Med. 1997 Sep;54(9):686-91 [9423584.001]
  • [Cites] Am J Ind Med. 1999 Mar;35(3):287-94 [9987562.001]
  • [Cites] Occup Environ Med. 2005 Apr;62(4):231-6 [15778255.001]
  • [Cites] Chem Biol Interact. 2005 May 30;153-154:9-21 [15935796.001]
  • [Cites] Chem Biol Interact. 2005 May 30;153-154:43-53 [15935799.001]
  • [Cites] Occup Med (Lond). 2007 May;57(3):177-85 [17244595.001]
  • [Cites] Cancer Causes Control. 2008 Feb;19(1):13-23 [17906934.001]
  • [Cites] Environ Health Perspect. 2008 Mar;116(3):370-4 [18335105.001]
  • [Cites] Am J Ind Med. 2008 Nov;51(11):803-11 [18651579.001]
  • [Cites] Am J Ind Med. 2002 Dec;42(6):474-80 [12439870.001]
  • [Cites] Scand J Work Environ Health. 2003 Feb;29(1):51-9 [12630436.001]
  • [Cites] Occup Environ Med. 2003 Sep;60(9):676-9 [12937190.001]
  • [Cites] Epidemiology. 2003 Sep;14(5):569-77 [14501272.001]
  • [Cites] Occup Environ Med. 2004 Mar;61(3):270-4 [14985523.001]
  • [Cites] Am J Ind Med. 1997 Mar;31(3):287-95 [9055951.001]
  • (PMID = 20584305.001).
  • [ISSN] 1476-069X
  • [Journal-full-title] Environmental health : a global access science source
  • [ISO-abbreviation] Environ Health
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] J64922108F / Benzene
  • [Number-of-references] 23
  • [Other-IDs] NLM/ PMC2903550
  •  go-up   go-down


7. El Rassi F, Arellano M: Update on optimal management of acute myeloid leukemia. Clin Med Insights Oncol; 2013;7:181-97
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on optimal management of acute myeloid leukemia.
  • Acute myeloid leukemia (AML) represents a malignant accumulation of immature myeloid cells in the marrow, presenting with impaired hematopoiesis and its attendant complications, including bleeding, infection, and organ infiltration.
  • However, the majority of AML patients who are not in the favorable category succumb to the disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23997579.001).
  • [Journal-full-title] Clinical Medicine Insights. Oncology
  • [ISO-abbreviation] Clin Med Insights Oncol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3748090
  • [Keywords] NOTNLM ; AML / management / prognosis
  •  go-up   go-down


8. Azad A, Rajwa B, Pothen A: Immunophenotype Discovery, Hierarchical Organization, and Template-Based Classification of Flow Cytometry Samples. Front Oncol; 2016;6:188
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We summarize a set of samples belonging to a biological class or category with a statistically derived template for the class.
  • We have applied the template-based scheme to analyze several datasets, including one representing a healthy immune system and one of acute myeloid leukemia (AML) samples.
  • However, we identified thirteen immunophenotypes corresponding to subtypes of AML and were able to distinguish acute promyelocytic leukemia (APL) samples with the markers provided.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27630823.001).
  • [ISSN] 2234-943X
  • [Journal-full-title] Frontiers in oncology
  • [ISO-abbreviation] Front Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC5005935
  • [Keywords] NOTNLM ; classification / clusters / flow cytometry / matching / meta-clusters / template
  •  go-up   go-down


9. Becker PS, Kantarjian HM, Appelbaum FR, Petersdorf SH, Storer B, Pierce S, Shan J, Hendrie PC, Pagel JM, Shustov AR, Stirewalt DL, Faderl S, Harrington E, Estey EH: Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol; 2011 Oct;155(2):182-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia.
  • This phase I/II study was conducted to determine the maximum tolerated dose, toxicity, and efficacy of clofarabine in combination with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming (GCLAC), in the treatment of patients with relapsed or refractory acute myeloid leukaemia (AML).
  • Multivariate analysis showed that responses to GCLAC were independent of age, cytogenetic risk category, and number of prior salvage regimens.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2011 Blackwell Publishing Ltd.
  • (PMID = 21848522.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA015704; United States / NCI NIH HHS / CA / R01 CA138720; United States / NCRR NIH HHS / RR / UL1 RR025014
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  • [Other-IDs] NLM/ NIHMS771286; NLM/ PMC4834701
  •  go-up   go-down


10. Weinberg OK, Pozdnyakova O, Campigotto F, DeAngelo DJ, Stone RM, Neuberg D, Hasserjian RP: Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia. Mod Pathol; 2015 Jul;28(7):965-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia.
  • The 2008 WHO classification of acute myeloid leukemia includes a category of acute myeloid leukemia with myelodysplasia-related changes; however, the significance of multilineage dysplasia alone is controversial and its reproducibility has not been evaluated in acute myeloid leukemia.
  • We performed an in-depth analysis of morphologic dysplasia in 159 de novo acute myeloid leukemia cases lacking myelodysplasia-related cytogenetic abnormalities.
  • Using the 2008 WHO criteria, there were 89 acute myeloid leukemia-not otherwise specified (56%) and 43 acute myeloid leukemia with myelodysplasia-related changes (27%), while 27 cases were ambiguous as to myelodysplasia-related changes status due to limited maturing cells (acute myeloid leukemia-not evaluable, 17%).
  • On multivariable analysis, neither acute myeloid leukemia with myelodysplasia-related changes nor acute myeloid leukemia-not evaluable showed significantly different event-free survival compared with acute myeloid leukemia-not otherwise specified in the 137 patients treated with induction chemotherapy.
  • Our findings indicate that the current 2008 WHO definition of multilineage dysplasia in acute myeloid leukemia in its current form is not optimal, and that the use of a more restricted definition of morphologic dysplasia results in more relevant risk stratification that is independent of other conventional prognostic factors.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Megakaryocytes / pathology. Myeloid Cells / pathology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25975285.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement